Correlation Between Depression Scores and Serum NF-ĸB/NLRP3 Axis, Biotinidase, and HMGB After Treatment With Isotretinoin in Patients With Acne Vulgaris - Trial NCT06242288
Access comprehensive clinical trial information for NCT06242288 through Pure Global AI's free database. This Phase 3 trial is sponsored by Mostafa Bahaa and is currently Recruiting. The study focuses on Acne Vulgaris. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mostafa Bahaa
Tanta University
Timeline & Enrollment
Phase 3
Jan 30, 2024
Jan 20, 2026
Primary Outcome
change in biotinidase level
Summary
Acne is a chronic inflammatory disease of the pilosebaceous unit resulting from
 androgen-induced increased sebum production, altered keratinization, inflammation, and
 bacterial colonization of hair follicles on the face, neck, chest, and back by, Cutibacterium
 acnes. Although all age groups can be affected, it is primarily a disease of adolescence.
 Treatment selection is based on disease severity, patient preference, and tolerability.
 Isotretinoin is drug of chioce used for moderate and severe acne. Isotretinoin results in a
 significant reduction in sebum production, influences comedogenesis, lowers surface and
 ductal c. acnes and has anti-inflammatory properties. Biotin deficiency may be caused by
 insufficient dietary uptake of biotin, drug- vitamin interactions and increased biotin
 catabolism during pregnancy and in smokers. Biotin deficiency can also be precipitated by
 decreased activities of biotinidase, which plays a central role in the intestinal absorption
 of biotin
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06242288
Non-Device Trial